The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
[ X ]
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wolters Kluwer Medknow Publications
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: The discovery of the epidermal growth factor receptor (EGFR) mutation, especially in adenocarcinoma, has led to a major change in the treatment of non-small-cell lung cancer (NSCLC). This study investigated the relationship between the EGFR mutation status and the carcinoembryonic antigen (CEA) levels at the time of diagnosis. Materials and Methods: A total of 102 patients with EGFR mutation and tested CEA levels were recruited for this study. Of the patients, 24 were EGFR mutants (23.5%), while 78 patients (76.5%) did not harbor any EGFR mutations. Results: The CEA levels did not differ across groups. Additionally, the CEA levels were analyzed between female and male patients separately due to EGFR mutations; no difference was observed. When the CEA levels were categorized as positive or negative based on different cut-off values, such as 5 and 10 ng/ml, no statistical difference was found between groups. Conclusion: In this study, no relationship between EGFR mutation and pre-treatment CEA levels was observed. Despite positive trials having shown a predictive value of CEA levels for EGFR mutation, more clinical trials are needed to elucidate the racial, clinical, and pathological differences of the study populations. Most studies have been located in the Far East, but new trials in Caucasian, African, and Hispanic populations are still lacking.
Açıklama
Anahtar Kelimeler
CEA, EGFR mutation, lung adenocarcinoma, non-small-cell lung cancer
Kaynak
Journal of Cancer Research and Therapeutics
WoS Q Değeri
Q4
Scopus Q Değeri
Q3
Cilt
20
Sayı
3
